NASDAQ:ASMB Assembly Biosciences (ASMB) Stock Price, News & Analysis → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Free ASMB Stock Alerts $13.02 -0.36 (-2.69%) (As of 11:02 AM ET) Add Compare Share Share Today's Range$13.02▼$13.2050-Day Range$9.60▼$13.5852-Week Range$7.69▼$20.04Volume12,020 shsAverage Volume29,393 shsMarket Capitalization$71.35 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Assembly Biosciences alerts: Email Address Assembly Biosciences MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.64% of Float Sold ShortDividend StrengthN/ASustainability-0.71Upright™ Environmental ScoreNews Sentiment0.02Based on 26 Articles This WeekInsider TradingAcquiring Shares$233,991 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($14.29) to ($14.77) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.34 out of 5 starsMedical Sector753rd out of 939 stocksPharmaceutical Preparations Industry346th out of 433 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Assembly Biosciences. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.64% of the float of Assembly Biosciences has been sold short.Short Interest Ratio / Days to CoverAssembly Biosciences has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Assembly Biosciences has recently increased by 207.14%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAssembly Biosciences does not currently pay a dividend.Dividend GrowthAssembly Biosciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAssembly Biosciences has received a 74.27% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for infectious diseases", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Assembly Biosciences is -0.71. Previous Next 2.2 News and Social Media Coverage News SentimentAssembly Biosciences has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 26 news articles for Assembly Biosciences this week, compared to 24 articles on an average week.MarketBeat Follows4 people have added Assembly Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Assembly Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $233,991.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.10% of the stock of Assembly Biosciences is held by insiders.Percentage Held by InstitutionsOnly 19.92% of the stock of Assembly Biosciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Assembly Biosciences are expected to decrease in the coming year, from ($14.29) to ($14.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Assembly Biosciences is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Assembly Biosciences is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAssembly Biosciences has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsUrgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.Click here to get my exclusive report NOW >>> About Assembly Biosciences Stock (NASDAQ:ASMB)Assembly Biosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study. It is also involved in novel small molecule approaches for HBV and hepatitis delta virus (HDV) comprising an orally bioavailable HBV/HDV entry inhibitor and liver-focused interferon-a receptor agonist. In addition, the company develops Herpesvirus programs, such as ABI-5366 HSV-2, a long-acting helicase inhibitor; and pan-herpes non-nucleoside polymerase inhibitors for transplant-associated infections. Further, Assembly Biosciences, Inc. has collaboration agreement with BeiGene, Ltd. to develop and commercialize the novel core inhibitor product candidates for chronic HBV infection in the People's Republic of China, Hong Kong, Taiwan, and Macau; and clinical trial collaboration agreement with Arbutus Biopharma Corporation to conduct a randomized, multi-center, and open-label clinical trials, as well as agreement with Antios Therapeutics, Inc. for triple combination therapy. The company also has license agreement with Indiana University Research and Technology Corporation for HBV research, as well as a partnership with Gilead Sciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.Read More ASMB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ASMB Stock News HeadlinesMarch 28, 2024 | americanbankingnews.comShort Interest in Assembly Biosciences, Inc. (NASDAQ:ASMB) Grows By 207.1%March 27, 2024 | msn.com'Will Keep Fighting': Delhi Ministers, AAP MLAs Protest Outside Delhi Assembly Over Kejriwal's Arrest —WATCHMarch 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.March 27, 2024 | msn.comBJP Fields Haryana CM Nayab Saini From Karnal Assembly; Navneet Rana From Amravati Lok SabhaMarch 27, 2024 | msn.comNY Assembly Speaker Heastie refuses to back tougher sentences for criminals who attack retail workersMarch 27, 2024 | msn.comEx-NY Assembly Speaker Sheldon Silver left jailed, bedridden and alone in final days after epic fall from power: reportMarch 27, 2024 | msn.comEx-Assembly Speaker Sheldon Silver left jailed, bedridden and alone in final days after epic fall from power: reportMarch 27, 2024 | americanbankingnews.comAssembly Biosciences (NASDAQ:ASMB) Share Price Crosses Above 200-Day Moving Average of $10.54March 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.March 26, 2024 | msn.comDelhi Assembly special session is going to be held tomorrowMarch 26, 2024 | msn.comAssembly Hall crowd gives IU women's basketball 'push to get to the finish line,' Sweet 16March 26, 2024 | msn.comNo proof to show graft money powered campaign for 2022 Goa Assembly polls: AAP State chief Amit PalekarMarch 25, 2024 | bbc.comThe Assembly - Michael Sheen on facing the grilling of a lifetime: “I really had no idea what I was going to be asked”March 25, 2024 | investorplace.comASMB Stock Earnings: Assembly Biosciences Misses EPS for Q2 2023March 25, 2024 | msn.comCalvary Assembly of God hosts annual Easter egg huntMarch 25, 2024 | msn.comBJP Releases First Candidates List For Sikkim Assembly ElectionsMarch 24, 2024 | msn.comNY Assembly ethics chair slammed for fundraiser days before budget deadline: ‘What kind of message does it send?’March 23, 2024 | bizjournals.comBill to support Tennessee's live music industry gains momentum in Tennessee General AssemblyMarch 22, 2024 | barrons.comUN General Assembly Seeks Guidelines To Address Risks Of AIMarch 22, 2024 | news.yahoo.comLibby Assembly of God Church hosting noted authorMarch 22, 2024 | msn.comLabor group head suddenly resigns days after romance between its lobbyist, NY Assembly Speaker Carl Heastie revealedMarch 21, 2024 | yahoo.comUN General Assembly calls for guidelines on AI's risks, rewardsMarch 21, 2024 | msn.comNaveen meets BJD leaders to select candidates for 4 Lok Sabha seats, 28 Assembly segmentsMarch 21, 2024 | msn.comParliamentary delegation led by Rajya Sabha Dy Chairman Harivansh to attend 148th Assembly of IPU in GenevaMarch 21, 2024 | msn.comDemocrats are not representing the people: NY State Assembly candidate Ramses FriasMarch 21, 2024 | msn.comSons Of Six Former CMs In Fray In Andhra Pradesh Assembly PollsMarch 21, 2024 | msn.comGeneral Assembly races test clout of Democrat leadersSee More Headlines Receive ASMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Assembly Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ASMB CUSIP92282210 CIK1426800 Webwww.assemblybio.com Phone(833) 509-4583Fax646-706-5101Employees68Year Founded2005Profitability EPS (Most Recent Fiscal Year)($17.0468) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-93,090,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-116.42% Return on Assets-95.89% Debt Debt-to-Equity RatioN/A Current Ratio6.96 Quick Ratio6.96 Sales & Book Value Annual Sales$6.25 million Price / Sales11.73 Cash FlowN/A Price / Cash FlowN/A Book Value$20.34 per share Price / Book0.66Miscellaneous Outstanding Shares5,480,000Free Float5,256,000Market Cap$73.32 million OptionableOptionable Beta0.56 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Jason A. Okazaki (Age 48)CEO, President & Director Comp: $869.28kDr. William E. Delaney IV (Age 52)Ph.D., Chief Scientific Officer Comp: $664.4kDr. Uri A. Lopatin M.D. (Age 52)Co-Founder and Clinical & Scientific Advisor Comp: $608.55kDr. Adam ZlotnickCo-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory BoardJeanette M BjorkquistExecutive Director of Accounting & TreasuryShannon RyanSenior Vice President of Investor Relations, Corporate Affairs & Alliance ManagementMs. Jennifer A. Troia MHRODSHRM-SCP, SPHR, Chief Human Resources OfficerDr. Nicole S. White Ph.D.Chief Manufacturing OfficerDr. Anuj Gaggar M.D.Ph.D., Chief Medical OfficerMr. Thomas E. Rollins (Age 68)Executive Officer Comp: $472.55kMore ExecutivesKey CompetitorsSol-Gel TechnologiesNASDAQ:SLGLCumberland PharmaceuticalsNASDAQ:CPIXStrongbridge BiopharmaNASDAQ:SBBPNektar TherapeuticsNASDAQ:NKTROmerosNASDAQ:OMERView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 99,092 shares on 3/11/2024Ownership: 42.684%Vanguard Group Inc.Bought 99,092 shares on 2/15/2024Ownership: 42.676%Citadel Advisors LLCBought 6,200 shares on 2/15/2024Ownership: 0.000%Northern Trust CorpBought 23,066 shares on 2/13/2024Ownership: 0.199%Simplex Trading LLCBought 200 shares on 2/2/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ASMB Stock Analysis - Frequently Asked Questions How have ASMB shares performed in 2024? Assembly Biosciences' stock was trading at $9.8412 at the beginning of 2024. Since then, ASMB shares have increased by 34.1% and is now trading at $13.20. View the best growth stocks for 2024 here. Are investors shorting Assembly Biosciences? Assembly Biosciences saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 60,200 shares, an increase of 207.1% from the February 29th total of 19,600 shares. Based on an average daily volume of 29,900 shares, the days-to-cover ratio is presently 2.0 days. Approximately 1.6% of the shares of the stock are short sold. View Assembly Biosciences' Short Interest. How were Assembly Biosciences' earnings last quarter? Assembly Biosciences, Inc. (NASDAQ:ASMB) announced its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($4.92) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($6.84) by $1.92. The biopharmaceutical company had revenue of $6.25 million for the quarter. When did Assembly Biosciences' stock split? Assembly Biosciences shares reverse split on Monday, February 12th 2024. The 1-12 reverse split was announced on Monday, February 12th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What is John McHutchison's approval rating as Assembly Biosciences' CEO? 8 employees have rated Assembly Biosciences Chief Executive Officer John McHutchison on Glassdoor.com. John McHutchison has an approval rating of 80% among the company's employees. 76.0% of employees surveyed would recommend working at Assembly Biosciences to a friend. What other stocks do shareholders of Assembly Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Assembly Biosciences investors own include BioDelivery Sciences International (BDSI), Exelixis (EXEL), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS), AVEO Pharmaceuticals (AVEO), Sorrento Therapeutics (SRNE), AbbVie (ABBV), BioCryst Pharmaceuticals (BCRX), Gilead Sciences (GILD) and Blueprint Medicines (BPMC). Who are Assembly Biosciences' major shareholders? Assembly Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (42.68%), Vanguard Group Inc. (42.68%), Federated Hermes Inc. (0.46%), Acuitas Investments LLC (0.40%), Northern Trust Corp (0.20%) and Marquette Asset Management LLC (0.08%). Insiders that own company stock include Alexander Schornstein, Jason A Okazaki, Jeanette M Bjorkquist, John G Mchutchison, Luisa M Stamm, Michael P Samar, Nicole S White, Timothy A Springer, William E Iv Delaney and William E Iv Delaney. View institutional ownership trends. How do I buy shares of Assembly Biosciences? Shares of ASMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ASMB) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assembly Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.